Epsilon Molecular Engineering

Saitama, Japan· Est. 2016

Japanese biotech using proprietary cDNA display and VHH libraries to discover next-generation antibodies and peptides for therapeutics and diagnostics.

epsilon-mol.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

Japanese biotech using proprietary cDNA display and VHH libraries to discover next-generation antibodies and peptides for therapeutics and diagnostics.

Unspecified - Platform for multiple areas

Technology Platform

Proprietary 'The Month' platform combining the PharmaLogical® VHH antibody library (10^13-14 diversity) with cDNA display technology for high-throughput, in vitro screening of functional biomolecules.

Opportunities

Growing demand for next-generation antibody therapeutics and diagnostics, particularly for targets challenging to conventional antibodies, coupled with increasing preference for animal-free discovery methods.

Risk Factors

Early-stage platform company with unproven clinical translation; faces competition from established antibody discovery platforms and larger biopharma companies; limited disclosed pipeline or partnerships.

Competitive Landscape

Competes with other VHH/antibody discovery platforms (e.g., Ablynx/Sanofi, Abcam services) and in vitro display technologies; differentiates via combined proprietary library and cDNA display for speed, diversity, and cruelty-free process.

More companies in Japan →